Rigel Q3 net income $12.4M vs year-ago loss; revenue $55.3M, led by TAVALISSE +8%

RIGEL PHARMACEUTICALS INC

2024-Q3 EPS reported $0.18 revenue$121,682,000

Total Q3 revenue $55.3M; net income $12.4M ($0.71 basic EPS) vs net loss $5.7M in Q3 2023.
TAVALISSE net sales $26.3M (+8% YoY); REZLIDHIA $5.5M (+107% YoY); GAVRETO $7.1M (first full quarter).
Received $10M upfront from Kissei license for REZLIDHIA in Japan, Korea, Taiwan; up to $152.5M milestones.
R289 Phase 1b in LR-MDS: RBC-TI/hematologic improvement in 36% at doses ≥500 mg QD; median duration 29 weeks.
Cash and investments $61.1M at Sep 30, up from $49.1M at Jun 30 and $56.9M at Dec 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.